The Zhitong Finance App learned that VogenX (VOGX.US), a biotech company that focuses on developing treatments for endocrine and metabolic disorders and is in the phase 2b clinical phase, announced its initial public offering (IPO) terms on Wednesday. The Raleigh, North Carolina-based company plans to raise $75 million by issuing 6.3 million shares in the price range of $11 to $13 per share. At the midpoint of the proposed range, Vogenx's fully diluted market capitalization would reach $173 billion.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.